Phase 2
N=226
A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects
Osteoporosis
Bottom Line
View on ClinicalTrials.gov: NCT00306189 ↗Enrolled (actual)
226
Serious AEs
7.6%
Results posted
Jan 2010
Primary outcome: Primary: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 — .46; 5.71; 6.73; 7.45 Percent Change from Baseline — p=<0.0001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- 100 mg AMG 162 (Drug); 60 mg AMG 162 (Drug); 14 mg AMG 162 (Drug); Placebo (Drug)
- Age
- Pediatric, Adult, Older Adult
- Sex
- Female
- Sponsor
- Amgen
- Primary completion
- Jun 2007
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 |
.46; 5.71; 6.73; 7.45 | <0.0001 sig |
Summary
The primary objective of this study is to assess the effect of AMG 162 (denosumab) treatment on the lumbar spine BMD at month 12 and safety profile across the dose range tested (14, 60 and 100 mg SC once every 6 months) in Japanese postmenopausal osteoporotic subjects compared with those treated with placebo over 12 months.
Eligibility Criteria
Inclusion Criteria: - Ambulatory postmenopausal women. - BMD values (g/cm2, Hologic) must be lower than 0.714 at lumbar spine, 0.515 at femoral neck, 0.588 at total hip. - BMD values must not be lower than 0.535 at the lumbar spine, 0.406 at the femoral neck and 0.478 at the total hip. Exclusion Criteria: - Oral bisphosphonate treatments, PTH or PTH derivatives use within the last 12 months and administration of any of anti-osteoporotic treatments within the last 3 months before initial administration of the investigational product. - History of hypocalcemia. - More than two moderate vertebral fractures or any severe vertebral fracture.
Data sourced from ClinicalTrials.gov (NCT00306189). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.